Australian Pharmaceutical Industries Ltd (ASX: API) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Australian Pharmaceutical Industries Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$751.30 million
P/E Ratio
526.32
Dividend Yield
2.34%
Shares Outstanding
492.66 million
Earnings per share
0.003
Dividend per share
0.04
Year To Date Return
-13.58%
Earnings Yield
0.19%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Australian Pharmaceutical Industries Ltd (ASX: API)
Latest News
Consumer Staples & Discretionary Shares
Could this signal the next big acquisition for Wesfarmers (ASX:WES)?
Mergers & Acquisitions
Following the Wesfarmers (ASX:WES) API takeover? Here are some key dates to watch out for
Share Fallers
Why API, James Hardie, Magellan, and St Barbara shares are dropping
Share Market News
ASX 200 (ASX:XJO): Woolworths withdraws API proposal, tech shares rebound
Mergers & Acquisitions
API (ASX:API) share price crashes 12% after Woolworths withdraws takeover offer
Mergers & Acquisitions
Wesfarmers (ASX:WES) share price higher after receiving API takeover boost
Retail Shares
Is the Wesfarmers (ASX:WES) share price an opportunity right now?
Consumer Staples & Discretionary Shares
Woolworths (ASX:WOW) share price rises as boss courts API pharmacists
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 11 Nov 2021 | $0.0200 | 100.00% | Final | 15 Dec 2021 |
| 06 May 2021 | $0.0150 | 100.00% | Interim | 04 Jun 2021 |
| 11 Nov 2020 | $0.0200 | 100.00% | Final | 15 Dec 2020 |
| 13 Nov 2019 | $0.0400 | 100.00% | Final | 12 Dec 2019 |
| 02 May 2019 | $0.0375 | 100.00% | Interim | 31 May 2019 |
| 08 Nov 2018 | $0.0400 | 100.00% | Final | 07 Dec 2018 |
| 03 May 2018 | $0.0350 | 100.00% | Interim | 01 Jun 2018 |
| 09 Nov 2017 | $0.0350 | 100.00% | Final | 08 Dec 2017 |
| 04 May 2017 | $0.0350 | 100.00% | Interim | 02 Jun 2017 |
| 03 Nov 2016 | $0.0350 | 100.00% | Final | 09 Dec 2016 |
| 05 May 2016 | $0.0250 | 100.00% | Interim | 03 Jun 2016 |
| 04 Nov 2015 | $0.0250 | 100.00% | 04 Dec 2015 | |
| 06 May 2015 | $0.0200 | 100.00% | 05 Jun 2015 | |
| 12 Nov 2014 | $0.0200 | 100.00% | 12 Dec 2014 | |
| 07 May 2014 | $0.0150 | 100.00% | 06 Jun 2014 | |
| 11 Nov 2011 | $0.0150 | 0.00% | Final | 15 Dec 2011 |
API ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Australian Pharmaceutical Industries Ltd
Australian Pharmaceutical Industries Ltd (ASX: API) is an Australian company with three key areas of operation: retail, wholesale distribution and business advisory. The company is probably best known for its retail pharmacy and health and beauty brands, Soul Pattinson and Priceline.
Priceline was acquired by API in 2004 and has more than 420 stores Australia-wide. Priceline stores are wholly owned by API whereas Priceline Pharmacies are operated under a franchise model.
In addition to its pharmacy brands, API owns a chain of 57 cosmetic, skin and laser hair removal clinics in Australia and New Zealand called Clear Skincare Clinics. It also produces a range of products under the Clear Skincare brand which it sells through Priceline Pharmacy.
API’s operations include retail services which encompass marketing programs and business advice.
API was established in 1910 and listed on the ASX in 1997. The API share price was hit hard by the February/March 2020 bear market, falling as low as $1 on 23 March. Since then, as at October 2020, the API share price has continued trading at between $1 and $1.20.
API Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 28 Jan 2022 | $1.53 | $0.03 | 2.01% | 4,026,086 | $1.50 | $1.53 | $1.50 |
| 27 Jan 2022 | $1.50 | $0.00 | 0.00% | 3,370,476 | $1.50 | $1.51 | $1.49 |
| 25 Jan 2022 | $1.50 | $-0.01 | -0.66% | 4,452,770 | $1.51 | $1.52 | $1.50 |
| 24 Jan 2022 | $1.52 | $0.00 | 0.00% | 1,364,288 | $1.51 | $1.52 | $1.51 |
| 21 Jan 2022 | $1.51 | $-0.01 | -0.66% | 4,340,570 | $1.52 | $1.52 | $1.51 |
| 20 Jan 2022 | $1.52 | $0.00 | 0.00% | 1,731,524 | $1.52 | $1.53 | $1.52 |
| 19 Jan 2022 | $1.52 | $0.01 | 0.66% | 1,016,598 | $1.52 | $1.52 | $1.52 |
| 18 Jan 2022 | $1.52 | $-0.01 | -0.66% | 365,624 | $1.52 | $1.52 | $1.52 |
| 17 Jan 2022 | $1.52 | $0.01 | 0.66% | 702,034 | $1.52 | $1.52 | $1.52 |
| 14 Jan 2022 | $1.52 | $0.00 | 0.00% | 833,031 | $1.52 | $1.52 | $1.52 |
| 13 Jan 2022 | $1.52 | $-0.01 | -0.66% | 1,631,678 | $1.52 | $1.53 | $1.52 |
| 12 Jan 2022 | $1.52 | $0.01 | 0.66% | 575,312 | $1.52 | $1.53 | $1.52 |
| 11 Jan 2022 | $1.52 | $0.00 | 0.00% | 403,807 | $1.52 | $1.52 | $1.52 |
| 10 Jan 2022 | $1.52 | $0.00 | 0.00% | 2,820,858 | $1.52 | $1.52 | $1.52 |
| 07 Jan 2022 | $1.52 | $-0.22 | -12.72% | 4,975,821 | $1.53 | $1.54 | $1.51 |
| 06 Jan 2022 | $1.73 | $-0.01 | -0.57% | 1,332,922 | $1.74 | $1.75 | $1.72 |
| 05 Jan 2022 | $1.74 | $0.01 | 0.58% | 295,674 | $1.74 | $1.74 | $1.73 |
| 04 Jan 2022 | $1.73 | $0.00 | 0.00% | 281,278 | $1.73 | $1.74 | $1.73 |
| 31 Dec 2021 | $1.73 | $0.00 | 0.00% | 292,107 | $1.73 | $1.74 | $1.73 |
| 30 Dec 2021 | $1.73 | $0.00 | 0.00% | 148,928 | $1.73 | $1.74 | $1.73 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 15 Oct 2021 | Richard Vincent | Expiry | 416 | $633,770 |
As advised by the company. 1,482,011 - Performance Rights
Performance rights lapsed under API's Long Term Incentive Plan |
| 15 Oct 2021 | Richard Vincent | Issued | 160 | $244,568 |
Issue of securities. 1,898,965 - performance rights
|
| 03 Feb 2021 | Richard Vincent | Issued | 825 | $1,056,512 |
Issue of securities. 1,738,065 - performance rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Richard Craig Vincent | Chief Executive OfficerManaging Director | Feb 2017 |
Mr Vincent started his professional career in finance with Bridgestone before moving to Britax Rainsfords where he was CFO. He joined FH Faulding & Co Limited (ultimately acquired by the Mayne Group) in 1998 and remained with that company until 2005, during which time he held a number of senior leadership roles, including responsibility for the pharmacy distribution, retail merchandise and generic pharmaceutical development. Mr Vincent joined API in 2005. He has held a number of general management roles including pharmacy distribution and business development, strategy, supply chain, franchise recruitment, IT, manufacturing and mergers and acquisition. Mr Vincent is the Chair of the National Pharmaceutical Services Association and was also a Director of CH2 Holdings Pty Ltd from 2006 to 2015.
|
| Mr Kenneth William Gunderson-Briggs | Non-Executive DirectorNon-Executive Chairman | May 2014 |
Mr Gunderson-Briggs is a chartered accountant in public practice, registered company auditor and public company Director, with experience in finance and the retail franchise sectors. Mr Gunderson-Briggs was a Director of Glenaeon Rudolf Steiner School Limited from 2009 until May 2018, and its Chair from 2013 until May 2018.
|
| Ms Lee Ausburn | Non-Executive Director | Oct 2008 |
Ms Ausburn is a pharmacist with experience in retail and hospital pharmacy and in academia. She had a long career in the pharmaceutical industry with Merck Sharp and Dohme (Australia) Pty Ltd and was previously Vice President, Asia, for Merck and Co Inc with responsibility for the company's operations across Asia. Ms Ausburn was President, Pharmacy Faculty Foundation, University of Sydney until December 2017.
|
| Ms Jennifer (Jenny) Mitchell Macdonald | Non-Executive Director | Nov 2017 |
Ms Macdonald has a background in financial and general management roles across a range of industry sectors including fast moving consumer goods, travel and digital media. Ms Macdonald was previously Chief Financial Officer and Interim Chief Executive Officer at Helloworld Travel and Chief Financial Officer and General Manager International at REA Group.
|
| Ms Janine Suzanne Allis | Non-Executive Director | Oct 2020 |
Ms Allis is a businesswoman with experience in retail and franchising. Ms Allis founded Boost Juice Bars and the Retail Zoo group of food retail brands and has led innovation in digital marketing and customer engagement. Ms Allis has won numerous retail and franchise awards and has been appointed an Ambassador to the United Nations High Commission for Refugees. She is currently a non-executive Director of the Olivia Newton-John Foundation and was previously a director of the Hawthorn Football Club. She is Member of People and Remuneration Committee.
|
| Mr Clive Stiff | Non-Executive Director | Dec 2020 |
Mr Stiff has over 35 years' experience in fast moving consumer goods. He is the former CEO of Unilever Australia & New Zealand and prior to that held a range of senior management roles locally with Goodman Fielder and internationally with Procter & Gamble. Mr Stiff was previously the Chair of the Australian Food & Grocery Council, the Chair of T2 Tea and a non-executive director of Foodbank NSW & ACT. He is currently the non-executive Chair of All G Foods Pty Ltd, a member of the Quantium Advisory Board and a member of the Genpact Australian Advisory Council. He is an external advisor to Bain & Company and a member of the University of New South Wales Business School Advisory Council.
|
| Mr George Tambassis | Non-Executive Director | Jun 2021 |
Mr Tambassis is a pharmacist with over 35 years' operational experience in community pharmacies. He has served as a director of the Australian College of Pharmacy, as a director of an aged care facility and as a member of the Australian Community Pharmacy Authority. He was the inaugural President of the World Pharmacy Council and a member of the OECD's Associate Expert Group advising on pharmacy and health. Mr Tambassis served as a director on the Pharmacy Guild of Australia for 15 years including 7.5 as its National President, during which he was instrumental in concluding the 6th and 7th Community Pharmacy Agreements with the Commonwealth Government.
|
| Ms Anne Mustow | Company SecretaryGeneral Counsel | Jul 2019 |
-
|
| Peter Mendo | Chief Financial Officer |
-
|
|
| Anne Mustow | Company SecretaryGeneral Counsel |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Wesfarmers Limited | 95,068,472 | 19.30% |
| Citicorp Nominees Pty Limited | 80,571,205 | 16.35% |
| HSBC Custody Nominees (Australia) Limited | 64,649,846 | 13.12% |
| J P Morgan Nominees Australia Pty Limited | 47,045,778 | 9.55% |
| National Nominees Limited | 23,990,229 | 4.87% |
| Neweconomy Com Au Nominees Pty Limited <900 Account> | 10,875,648 | 2.21% |
| BNP Paribas Noms Pty Ltd <Drp> | 5,487,767 | 1.11% |
| BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 3,446,978 | 0.70% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 3,127,021 | 0.63% |
| Brispot Nominees Pty Ltd <House Head Nominee A/C> | 2,406,099 | 0.49% |
| J & P Chick Pty Limited <J & P Chick Pty Ltd S/F A/C> | 2,000,000 | 0.41% |
| Jum Pty Limited | 1,567,286 | 0.32% |
| Netwealth Investments Limited <Wrap Services A/C> | 1,564,064 | 0.32% |
| HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> | 1,562,450 | 0.32% |
| BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> | 1,502,889 | 0.31% |
| BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 1,461,003 | 0.30% |
| Dr Jeffrey Eric Dale Chick & Dr Pamela Hazel Chick | 1,260,000 | 0.26% |
| Mr Frederick Benjamin Warmbrand <Fb & Lj Warmbrand Super A/C> | 1,240,000 | 0.25% |
| UBS Nominees Pty Ltd | 898,087 | 0.18% |
| Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> | 889,410 | 0.18% |